WO2005004791A3 - Compounds and methods for the treatment and prevention of bacterial infection - Google Patents

Compounds and methods for the treatment and prevention of bacterial infection Download PDF

Info

Publication number
WO2005004791A3
WO2005004791A3 PCT/US2003/035733 US0335733W WO2005004791A3 WO 2005004791 A3 WO2005004791 A3 WO 2005004791A3 US 0335733 W US0335733 W US 0335733W WO 2005004791 A3 WO2005004791 A3 WO 2005004791A3
Authority
WO
WIPO (PCT)
Prior art keywords
bacterial infection
prevention
treatment
compounds
methods
Prior art date
Application number
PCT/US2003/035733
Other languages
French (fr)
Other versions
WO2005004791A2 (en
Inventor
R John Collier
Jimmy D Ballard
Rodney Tweten
Michael Mourez
Original Assignee
Harvard College
Univ Oklahoma
R John Collier
Jimmy D Ballard
Rodney Tweten
Michael Mourez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Univ Oklahoma, R John Collier, Jimmy D Ballard, Rodney Tweten, Michael Mourez filed Critical Harvard College
Priority to AU2003304316A priority Critical patent/AU2003304316A1/en
Publication of WO2005004791A2 publication Critical patent/WO2005004791A2/en
Publication of WO2005004791A3 publication Critical patent/WO2005004791A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides mutant forms of pore-forming toxins. These mutant toxins may be used in vaccines for the prevention of bacterial infection. Additionally, dominant negative mutants may be administered as therapeutics for the treatment of bacterial infection.
PCT/US2003/035733 2002-11-08 2003-11-10 Compounds and methods for the treatment and prevention of bacterial infection WO2005004791A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003304316A AU2003304316A1 (en) 2002-11-08 2003-11-10 Compounds and methods for the treatment and prevention of bacterial infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42498702P 2002-11-08 2002-11-08
US60/424,987 2002-11-08

Publications (2)

Publication Number Publication Date
WO2005004791A2 WO2005004791A2 (en) 2005-01-20
WO2005004791A3 true WO2005004791A3 (en) 2009-07-09

Family

ID=34061810

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035733 WO2005004791A2 (en) 2002-11-08 2003-11-10 Compounds and methods for the treatment and prevention of bacterial infection

Country Status (2)

Country Link
AU (1) AU2003304316A1 (en)
WO (1) WO2005004791A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
BE1022949B1 (en) * 2014-06-25 2016-10-21 Glaxosmithkline Biologicals S.A. IMMUNOGENIC COMPOSITION

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042473A1 (en) * 1998-02-18 1999-08-26 President And Fellows Of Harvard College Inhibition of toxin translocation
US20020039588A1 (en) * 2000-05-04 2002-04-04 Collier R. John Compounds and methods for the treatment and prevention of bacterial infection
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
WO1999042473A1 (en) * 1998-02-18 1999-08-26 President And Fellows Of Harvard College Inhibition of toxin translocation
US20020039588A1 (en) * 2000-05-04 2002-04-04 Collier R. John Compounds and methods for the treatment and prevention of bacterial infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARVAUD J-C ET AL.: "Clostridium perfringens Iota-toxin: mapping of receptor binding and Ia docking domains on Ib", INFECTION AND IMMUNITY, vol. 69, no. 4, April 2001 (2001-04-01), pages 2435 - 2441, XP002983507 *
MOUREZ M. ET AL.: "Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis", PNAS, vol. 100, no. 24, 25 November 2003 (2003-11-25), pages 13803 - 13808, XP002983508 *

Also Published As

Publication number Publication date
WO2005004791A2 (en) 2005-01-20
AU2003304316A8 (en) 2005-01-28
AU2003304316A1 (en) 2005-01-28

Similar Documents

Publication Publication Date Title
WO2001082788A3 (en) Compounds and methods for the treatment and prevention of bacterial infection
GB0112836D0 (en) Medicaments
MXPA03010790A (en) Nitrogen-containing bicyclic heterocycles for use as antibacterials.
DE60123276D1 (en) PIPERAZINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
AU2003291227A1 (en) Antibacterial agents
WO2004058144A3 (en) Antibacterial agents
TW200507841A (en) Antibacterial agents
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2004006858A3 (en) Compounds, compositions, and methods employing same
GB0217294D0 (en) Medicaments
AU2003901008A0 (en) Composition for the treatment and prevention of bacterial infections
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
WO2003082208A8 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2003088897A3 (en) Fab i inhibitors
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
AU2003303956A1 (en) Antibacterial agents
AU2002356868A1 (en) Methods for the prevention or treatment of bacterial and fungal infections
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
WO2006034001A3 (en) Methods of treating hiv infection
EP1663959A4 (en) Novel amidine compounds for treating microbial infections
WO2005118613A3 (en) Antibacterial amide macrocycles
PL374524A1 (en) Composition based on triethyl citrate for the treatment of bacterial infections of the skin
WO2005004791A3 (en) Compounds and methods for the treatment and prevention of bacterial infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP